Skip to main content

Table 1 Patient characteristics of the study population

From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer

Characteristic Percentage (%)/median (range)
MDACC (n = 616) JICR (n = 262)
Age (years) 60.3 (20–92) 62.1 (22–85)
Baseline CA-125 level (U/mL) 800 (7–33423) 927 (5–24880)
Nadir CA-125 level (U/mL) 10 (4–35) 10 (2–35)
Ethnic group
 White 481(78.1) 0 (0.0)
 Black 35 (5.7) 0 (0.0)
 Hispanic 76 (12.3) 0 (0.0)
 Eastern Asian 16 (2.6) 262 (100.0)
 Others * 8 (1.3) 0 (0.0)
Surgical residual
 <1 cm 366 (59.4) 142 (54.2)
 1–2 cm 19 (3.1) 7 (2.7)
 >2 cm 154 (25.0) 76 (29.0)
 Unknown 77 (12.5) 37 (14.1)
FIGO stage
 I 49 (8.0) 21 (8.0)
 II 36 (5.8) 15 (5.7)
 III 410 (66.6) 171 (65.3)
 IV 125 (20.3) 52 (19.8)
 Unknown 4 (0.6) 2 (0.8)
Neo-adjuvant chemotherapy 133 (21.2) 186 (71.0)
  1. FIGO the International Federation of Gynecology and Obstetrics.
  2. Others* including 5 Middle Eastern, and 3 Indian cases.